Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay
文献类型：期刊论文
| 作者 | Bunu, Samuel Jacob1,2,3,5; Cai, Haiyan4; Zhou, Zhaoyin2,3,6; Zhang, Yanlei4; Lai, Yue4; Wang, Guanli4; Song, Dongliang4; Wu, Chengkun7,8; Zheng, Hang9; Xu, Zhijian2,3,5
|
| 刊名 | RSC MEDICINAL CHEMISTRY
 |
| 出版日期 | 2025-05-06 |
| 页码 | 14 |
| DOI | 10.1039/d4md01008f |
| 英文摘要 | Thyroid hormone receptor-interacting protein-13 (TRIP13) is an AAA+ ATPase that regulates protein complex assembly and disassembly and is known to be a chromosomal instability gene with the ability to repair DNA double-strand breaks. TRIP13 overexpression has been linked to the proliferation and development of many human malignancies, including multiple myeloma (MM). Accordingly, TRIP13 is recognized as a potential drug target for anticancer drug development. Although some TRIP13 inhibitors have been reported, none are under clinical trial or approved for clinical use. This study aimed to identify novel small molecules as potential TRIP13 inhibitors structurally different from previously reported compounds through molecular modeling and bioassays. As a result, five compounds were successfully identified as novel TRIP13 inhibitors. F368-0183 showed the best antiproliferative activity with IC50 = 5.25 mu M (NCI-H929 cell line), comparable with the positive control DCZ0415 (IC50 = 9.64 mu M). Also, the cellular thermal shift assay confirmed that this compound could interact with the TRIP13 protein in MM cells. In addition, the AAA+ ATPase inhibitory bioassay demonstrated that the five compounds had better inhibitory activity than DCZ0415, having strong correlations with the calculated free energy perturbation (FEP). Further molecular dynamics simulation studies revealed that the novel compounds could significantly interact with 12 residues of TRIP13, especially R386, L139, R389, L135, S138, Y141, and G385. We also assessed the F368-0183 inhibition on a kinase panel, no other targets were found, but the potential binding to other target proteins of these compounds cannot be totally excluded. Therefore, the new molecular scaffolds of these compounds, their efficacy in suppressing MM cell line proliferation, and the displayed TRIP13 AAA+ ATPase inhibitory properties provide important clues for developing novel TRIP13-based multi-target anti-MM drugs. |
| WOS关键词 | MULTIPLE-MYELOMA ; DRUG-RESISTANCE ; AAA-ATPASE ; CHECKPOINT ; PROTEIN ; REV7 |
| 资助项目 | National Natural Science Foundation of China[2022YFA1004304] ; National Key Research and Development Program of China[82273851] ; National Key Research and Development Program of China[82322067] ; National Key Research and Development Program of China[82070224] ; National Natural Science Foundation of China[2022ANP10025] ; Alliance of International Science Organization (CAS-ANSO) Scholarship for Young Talents |
| WOS研究方向 | Biochemistry & Molecular Biology ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001481592400001 |
| 出版者 | ROYAL SOC CHEMISTRY |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/317611]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Cai, Haiyan; Xu, Zhijian; Shi, Jumei; Zhu, Weiliang |
| 作者单位 | 1.Niger Delta Univ, Fac Pharm, Dept Pharmaceut & Med Chem, Bayelsa, Nigeria 2.Chinese Acad Sci, State Key Lab Drug Res, Shanghai 201203, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China 4.Tongji Univ, Shanghai East Hosp, Sch Med, Dept Hematol, Shanghai 200120, Peoples R China 5.Univ Chinese Acad Sci, Sch Pharm, 19A Yuquan Rd, Beijing 100049, Peoples R China 6.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China 7.Natl Univ Def Technol, Natl Key Lab Parallel & Distributed Comp, Changsha 410073, Hunan, Peoples R China 8.Natl Univ Def Technol, Lab Digitizing Software Frontier Equipment, Changsha 410073, Hunan, Peoples R China 9.DP Technol, Beijing 100089, Peoples R China |
| 推荐引用方式 GB/T 7714 | Bunu, Samuel Jacob,Cai, Haiyan,Zhou, Zhaoyin,et al. Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay[J]. RSC MEDICINAL CHEMISTRY,2025:14. |
| APA | Bunu, Samuel Jacob.,Cai, Haiyan.,Zhou, Zhaoyin.,Zhang, Yanlei.,Lai, Yue.,...&Zhu, Weiliang.(2025).Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay.RSC MEDICINAL CHEMISTRY,14. |
| MLA | Bunu, Samuel Jacob,et al."Discovery of novel antimyeloma agents targeting TRIP13 by molecular modeling and bioassay".RSC MEDICINAL CHEMISTRY (2025):14. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。